ALK and non-small cell lung carcinoma: Patients with good performance status (ECOG PS 0–1) treated in the US real-world clinical setting for advanced NSCLC, with PD-L1 TPS ≥ 50%, and without EGFR/ALK/ROS1 genomic alterations, experienced a median rwToT of 7.4 months, similar to the treatment durations observed in clinical trials.